HomeSearchGlobal LocationsContact UsGenzyme Websites
About GenzymeOur ResearchOur ProductsOur Commitment
Genzyme

Corporate Info
Investors
News
Investor Events
Financial Reports
Guidance and Reconciliation
Research Pipeline
Analyst Coverage
Frequently Asked Questions
News
Partnering
Genzyme Events
Careers
Global Locations

News

Genzyme Releases

inv_genz_news_all Genzyme General News
August 25, 2008 Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
August 6, 2008 Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
July 23, 2008 Genzyme Reports Strong Second-Quarter Growth
July 17, 2008 Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
June 24, 2008 Genzyme and Isis complete licensing of mipomersen
June 17, 2008 Genzyme Files Applications for Approval of Mozobil in the United States and Europe
June 2, 2008 Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
May 7, 2008 Preliminary Results from Phase 2 Genzyme Study
April 25, 2008 FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
April 23, 2008 Genzyme Reports Strong First-Quarter Growth
April 22, 2008 Genzyme to Build New R&D Center in Beijing
April 21, 2008 Genzyme Provides Update on Myozyme® Manufacturing
April 14, 2008 Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
March 19, 2008 Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 10, 2008 Genzyme Announces Presentation of New Positive Data on Carticel®
March 6, 2008 Genzyme Launches Renvela® in the U.S. for Dialysis Patients
February 13, 2008 Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
February 1, 2008 University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program
February 1, 2008 Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration
January 15, 2008 Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
January 8, 2008 Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
January 7, 2008 Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
December 19, 2007 Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™
December 17, 2007 Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation
December 13, 2007 Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
December 5, 2007 Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
December 4, 2007 National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
November 13, 2007 Genzyme Receives FDA Response Letter on Synvisc-One™
October 29, 2007 Epicel™ Wins Marketing Approval for Severe Burn Victims
October 25, 2007 Genzyme and Sunway to Collaborate on Gene Therapy Program in China
October 24, 2007 Genzyme Reports Strong Earnings Growth in Third Quarter
October 23, 2007 Genzyme Launches Cholestagel® in Europe
October 22, 2007 Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
October 22, 2007 FDA Approves Genzyme's Renvela for Dialysis Patients
October 16, 2007 Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 15, 2007 Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
October 12, 2007 Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 12, 2007 Genzyme Recognized by Scientists as a Top Employer
October 10, 2007 Delaware Court Approves Bioenvision, Genzyme Joint Petition
October 10, 2007 Bioenvision and Genzyme File Petition in Delaware Court
October 4, 2007 Genzyme Receives Approval to Market Elaprase® in Japan
September 27, 2007 Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
September 26, 2007 Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
September 20, 2007 FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
September 18, 2007 Genzyme Begins Major Expansion of Boston Manufacturing Facility
August 29, 2007 Genzyme Announces Publication of DCOR Study in Kidney International
July 23, 2007 Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases


Search News Releases

 

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.